Personal Genomics Taiwan v. Pacific Biosciences: Federal Circuit Affirms Unpatentability
Personal Genomics Taiwan appealed a patentability ruling over US7767441B2 — a patent covering optical detection-based bioassay systems for biomolecule detection — against Pacific Biosciences. The Federal Circuit affirmed the finding of unpatentability, closing the dispute after 659 days.
Federal Circuit closes optical bioassay patent dispute — unpatentability stands
Personal Genomics Taiwan, Inc. filed Case No. 22-1554 at the Court of Appeals for the Federal Circuit on 21 March 2022, challenging an underlying invalidity or cancellation ruling affecting US7767441B2. That patent covers bioassay systems incorporating optical detection apparatuses and methods for detecting biomolecules — technology directly relevant to next-generation sequencing and molecular diagnostics platforms. Pacific Biosciences, Inc., a leading developer of long-read DNA sequencing instruments, was the opposing party.
The Federal Circuit issued its judgment on 9 January 2024, affirming the prior finding of unpatentability. The operative order — ‘AFFIRMED’ — confirms that the appellate panel identified no reversible legal error in the underlying proceeding’s conclusion that the claims of US7767441B2 are unpatentable. As a result, the patent’s claims cannot be enforced, and Pacific Biosciences faces no ongoing liability under those claims.
The 659-day duration suggests substantive appellate briefing rather than a procedural disposal, consistent with technically complex bioassay and optical-detection claim scope. What drove the ultimate affirmance — claim construction, prior art coverage, or written-description deficiency — is not specified in the public record. Personal Genomics Taiwan’s appellate options at the Federal Circuit are now exhausted; any further challenge would require a petition to the Supreme Court.
Filing to Unpatentable in 659 days
659 days — above median for Federal Circuit patent appeals, which typically resolve in 18–24 months
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means no reversible error found below
When the Federal Circuit ‘affirms,’ it confirms that the lower tribunal’s decision — here, a finding of unpatentability — was legally sound. The appellate panel applies deferential review to factual findings (substantial evidence) and de novo review to legal conclusions such as claim construction. An affirmance does not merely let the lower decision stand procedurally; it signals that the panel examined the merits and found no basis to disturb the outcome.
Appellate affirmanceUS7767441B2 is unenforceable — claims extinguished
For Personal Genomics Taiwan, the affirmance is dispositive. The patent claims subject to the invalidity or cancellation action have been adjudicated unpatentable, and that status is now confirmed at the Federal Circuit level. The company cannot assert these claims against Pacific Biosciences or any third party. Any licensing programme built around this patent in the optical bioassay space must be revisited. The only remaining avenue is a certiorari petition to the Supreme Court, which is rarely granted in patent matters.
Patent extinguishedPacific Biosciences clears the patent — design freedom confirmed
Pacific Biosciences successfully defended the unpatentability finding through appeal. With US7767441B2 now confirmed unpatentable, PacBio’s optical detection-based sequencing systems face no infringement exposure under this patent. The affirmance also raises the bar for any future attempt by Personal Genomics Taiwan to assert related patents in the same family, as the Federal Circuit’s reasoning may bear on claim scope and validity arguments in parallel proceedings.
FTO strengthenedBioassay optical detection space sees key blocking patent fall
The confirmed unpatentability of US7767441B2 removes a potential blocking position in the optical bioassay and single-molecule detection segment. Competitors developing systems for biomolecule detection via optical apparatuses — including fluorescence-based sequencing and lab-on-chip platforms — may now operate with greater freedom. However, participants should audit related continuation patents and divisionals in the same family, as holders sometimes retain enforceable claims even after one patent is cancelled.
Competitive freedom increasedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Personal Genomics Taiwan, Inc. | Company | Genomics IP holding entity — owner of US7767441B2 covering optical bioassay detection systemsSearch in Eureka ↗ |
| Defendant | Pacific Biosciences, Inc. | Company | Pacific Biosciences, Inc. — developer of long-read single-molecule DNA sequencing platformsSearch in Eureka ↗ |
| Plaintiff counsel | Michael Richard Fleming | Attorney | Counsel for Personal Genomics Taiwan, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Irell & Manella, LLP | Law Firm | Representing Personal Genomics Taiwan, Inc.Search in Eureka ↗ |
| Defendant counsel | Derek C. Walter | Attorney | Counsel for Pacific Biosciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Weil Gotshal & Manages, LLP | Law Firm | Representing Pacific Biosciences, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED’ — is unambiguous: the panel found no reversible error in the underlying tribunal’s determination of unpatentability for US7767441B2. At the appellate level, factual findings (such as prior art teachings) are reviewed for substantial evidence, while legal conclusions receive de novo scrutiny. An affirmance across both standards is a strong endorsement of the lower proceeding’s reasoning. For Personal Genomics Taiwan, no enforceable claims under this patent survive. For Pacific Biosciences, the ruling is final at the Federal Circuit level.
US7767441B2 — Bioassay system with optical detection for biomolecule analysis
US7767441B2 (application number US12/255044) covers a bioassay system that integrates optical detection apparatuses for identifying and measuring biomolecules. The technology sits at the intersection of photonics, microfluidics, and molecular biology — forming the detection substrate for applications including DNA sequencing, protein assays, and single-molecule analysis. The application date places this patent in an era of rapid advancement in fluorescence-based and zero-mode waveguide detection, both central to next-generation sequencing platforms.
In the context of the long-read sequencing market, optical bioassay detection patents have historically been used to create licensing leverage or block platform launches. US7767441B2’s confirmed unpatentability removes one such potential blocking position against Pacific Biosciences, whose SMRT sequencing technology relies heavily on optical detection of single molecules. For the broader sector — including Illumina, Oxford Nanopore, and emerging spatial biology platforms — the outcome signals that foundational optical bioassay claims face meaningful validity scrutiny at the Federal Circuit.
Should you run an FTO against US7767441B2 and its patent family?
Product and R&D teams developing bioassay systems with optical detection components — including fluorescence-based sequencers, single-molecule detection instruments, or lab-on-chip diagnostic platforms — should note that US7767441B2 has been confirmed unpatentable. However, freedom-to-operate is not fully established by one cancelled patent alone. Personal Genomics Taiwan may hold continuation or divisional applications derived from the same priority chain, which could carry similar claims in a narrower or differently drafted form.
PatSnap Eureka’s FTO Search Agent enables teams to map the full patent family around US7767441B2, identify co-pending continuations, and assess whether any surviving claims present risk. By combining citation analysis, claim-language comparison, and litigation history in one workflow, Eureka helps IP and R&D teams reach defensible FTO conclusions faster — particularly in fast-moving domains like genomics instrumentation where the patent landscape shifts with each sequencing generation.
Run a freedom-to-operate analysis on US7767441B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in genomics and optical bioassay patent disputes
Federal Circuit cases involving optical bioassay, single-molecule detection, and genomics instrument patents — comparable unpatentability appeals and invalidity challenges.
What this case signals for the genomics and bioassay IP landscape
A confirmed unpatentability at the Federal Circuit has lasting consequences for optical detection patent strategy across the genomics sector.
Unpatentability affirmance narrows enforcement options for genomics IP holders
When the Federal Circuit affirms an unpatentability finding, the result is binding and public. Any party that previously licensed or avoided US7767441B2 should reassess those arrangements. Royalty obligations tied to now-invalid claims are typically unenforceable, and licensees may have grounds to cease payments or renegotiate terms depending on contract language.
PacBio’s design-freedom win strengthens its competitive position in long-read sequencing
With the optical detection patent confirmed unpatentable, Pacific Biosciences can develop and commercialise its sequencing platforms without this particular IP overhang. For competitors and investors, this signals that PacBio’s freedom-to-operate in optical bioassay detection is judicially validated at the highest patent appellate level in the US.
Personal v Pacific — key questions answered
The Federal Circuit affirmed the unpatentability of US7767441B2 on 9 January 2024. The appellate court found no reversible error in the lower tribunal’s invalidity or cancellation decision, confirming that the patent claims are unpatentable and unenforceable.
US7767441B2 covers a bioassay system incorporating optical detection apparatuses for detecting biomolecules. This technology is foundational to fluorescence-based and single-molecule sequencing platforms. Its relevance to Pacific Biosciences’ SMRT sequencing instruments made it a commercially significant patent in the genomics detection space.
An affirmance at the Federal Circuit means the appellate panel reviewed the lower decision and found no reversible legal error. For a patent holder like Personal Genomics Taiwan, it means the unpatentability finding is final at this appellate level. The only remaining avenue is a certiorari petition to the US Supreme Court, which is rarely granted in patent cases.
Not automatically. Unpatentability of US7767441B2 does not extinguish continuation or divisional patents derived from the same priority application. Personal Genomics Taiwan may hold co-pending applications with differently drafted claims. A full family-tree analysis is advisable for any party seeking confirmed freedom-to-operate in the optical bioassay detection space.
Pacific Biosciences secured freedom-to-operate against US7767441B2, confirmed at the Federal Circuit. This removes a potential licensing demand or injunction risk over optical detection features in its sequencing platforms. The ruling strengthens PacBio’s IP position and may inform competitor FTO assessments and licensing negotiations in the broader genomics instrumentation market.
PatSnap Eureka searches patents and litigation data to answer instantly.